These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 37788341)

  • 1. Development of a Novel CLDN18.2-directed Monoclonal Antibody and Antibody-Drug Conjugate for Treatment of CLDN18.2-Positive Cancers.
    O'Brien NA; McDermott MSJ; Zhang J; Gong KW; Lu M; Hoffstrom B; Luo T; Ayala R; Chau K; Liang M; Madrid AM; Donahue TR; Glaspy JA; Presta L; Slamon DJ
    Mol Cancer Ther; 2023 Dec; 22(12):1365-1375. PubMed ID: 37788341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical Efficacy of the Antibody-Drug Conjugate CLDN6-23-ADC for the Treatment of CLDN6-Positive Solid Tumors.
    McDermott MSJ; O'Brien NA; Hoffstrom B; Gong K; Lu M; Zhang J; Luo T; Liang M; Jia W; Hong JJ; Chau K; Davenport S; Xie B; Press MF; Panayiotou R; Handly-Santana A; Brugge JS; Presta L; Glaspy J; Slamon DJ
    Clin Cancer Res; 2023 Jun; 29(11):2131-2143. PubMed ID: 36884217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic Cancer.
    Zhu G; Foletti D; Liu X; Ding S; Melton Witt J; Hasa-Moreno A; Rickert M; Holz C; Aschenbrenner L; Yang AH; Kraynov E; Evering W; Obert L; Lee C; Sai T; Mistry T; Lindquist KC; Van Blarcom T; Strop P; Chaparro-Riggers J; Liu SH
    Sci Rep; 2019 Jun; 9(1):8420. PubMed ID: 31182754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Claudin18.2-Specific Chimeric Antigen Receptor Engineered T Cells for the Treatment of Gastric Cancer.
    Jiang H; Shi Z; Wang P; Wang C; Yang L; Du G; Zhang H; Shi B; Jia J; Li Q; Wang H; Li Z
    J Natl Cancer Inst; 2019 Apr; 111(4):409-418. PubMed ID: 30203099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ZL-1211 Exhibits Robust Antitumor Activity by Enhancing ADCC and Activating NK Cell-mediated Inflammation in CLDN18.2-High and -Low Expressing Gastric Cancer Models.
    Konno H; Lin T; Wu R; Dai X; Li S; Wang G; Chen M; Li W; Wang L; Sun BC; Luo Z; Huang T; Chen Y; Zhang J; Ye Q; Bellovin D; Wan B; Kang L; Szeto C; Hsu K; Kabbarah O
    Cancer Res Commun; 2022 Sep; 2(9):937-950. PubMed ID: 36922936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the human MUC1-C oncoprotein with an antibody-drug conjugate.
    Panchamoorthy G; Jin C; Raina D; Bharti A; Yamamoto M; Adeebge D; Zhao Q; Bronson R; Jiang S; Li L; Suzuki Y; Tagde A; Ghoroghchian PP; Wong KK; Kharbanda S; Kufe D
    JCI Insight; 2018 Jun; 3(12):. PubMed ID: 29925694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a Humanized VHH Based Recombinant Antibody Targeting Claudin 18.2 Positive Cancers.
    Zhong W; Lu Y; Ma Z; He Y; Ding Y; Yao G; Zhou Z; Dong J; Fang Y; Jiang W; Wang W; Huang Y
    Front Immunol; 2022; 13():885424. PubMed ID: 35837391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A glypican-1-targeted antibody-drug conjugate exhibits potent tumor growth inhibition in glypican-1-positive pancreatic cancer and esophageal squamous cell carcinoma.
    Munekage E; Serada S; Tsujii S; Yokota K; Kiuchi K; Tominaga K; Fujimoto M; Kanda M; Uemura S; Namikawa T; Nomura T; Murakami I; Hanazaki K; Naka T
    Neoplasia; 2021 Sep; 23(9):939-950. PubMed ID: 34332450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers.
    Cardillo TM; Govindan SV; Sharkey RM; Trisal P; Arrojo R; Liu D; Rossi EA; Chang CH; Goldenberg DM
    Bioconjug Chem; 2015 May; 26(5):919-31. PubMed ID: 25915780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic efficacy, pharmacokinetic profiles, and toxicological activities of humanized antibody-drug conjugate Zt/g4-MMAE targeting RON receptor tyrosine kinase for cancer therapy.
    Yao HP; Feng L; Suthe SR; Chen LH; Weng TH; Hu CY; Jun ES; Wu ZG; Wang WL; Kim SC; Tong XM; Wang MH
    J Immunother Cancer; 2019 Mar; 7(1):75. PubMed ID: 30871619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MEN1309/OBT076, a First-In-Class Antibody-Drug Conjugate Targeting CD205 in Solid Tumors.
    Merlino G; Fiascarelli A; Bigioni M; Bressan A; Carrisi C; Bellarosa D; Salerno M; Bugianesi R; Manno R; Bernadó Morales C; Arribas J; Dusek RL; Ackroyd JE; Pham PH; Awdew R; Aud D; Trang M; Lynch CM; Terrett J; Wilson KE; Rohlff C; Manzini S; Pellacani A; Binaschi M
    Mol Cancer Ther; 2019 Sep; 18(9):1533-1543. PubMed ID: 31227646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor effect of antitissue factor antibody-MMAE conjugate in human pancreatic tumor xenografts.
    Koga Y; Manabe S; Aihara Y; Sato R; Tsumura R; Iwafuji H; Furuya F; Fuchigami H; Fujiwara Y; Hisada Y; Yamamoto Y; Yasunaga M; Matsumura Y
    Int J Cancer; 2015 Sep; 137(6):1457-66. PubMed ID: 25704403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of anti-claudin 18.2 monoclonal antibody zolbetuximab alone or combined with chemotherapy or programmed cell death-1 blockade in syngeneic and xenograft gastric cancer models.
    Nishibata T; Weng J; Omori K; Sato Y; Nakazawa T; Suzuki T; Yamada T; Nakajo I; Kinugasa F; Türeci Ö; Şahin U; Yoshida T
    J Pharmacol Sci; 2024 Jul; 155(3):84-93. PubMed ID: 38797537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel humanized MUC1 antibody-drug conjugate for the treatment of trastuzumab-resistant breast cancer.
    Wu G; Li L; Qiu Y; Sun W; Ren T; Lv Y; Liu M; Wang X; Tao H; Zhao L; Cao J; He L; Li H; Gu H
    Acta Biochim Biophys Sin (Shanghai); 2021 Dec; 53(12):1625-1639. PubMed ID: 34586349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CLDN18.2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor-directed T-cell activation.
    Gao J; Wang Z; Jiang W; Zhang Y; Meng Z; Niu Y; Sheng Z; Chen C; Liu X; Chen X; Liu C; Jia K; Zhang C; Liao H; Jung J; Sung E; Chung H; Zhang JZ; Zhu AX; Shen L
    J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37364935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel Antibody Drug Conjugates Targeting Tumor-Associated Receptor Tyrosine Kinase ROR2 by Functional Screening of Fully Human Antibody Libraries Using Transpo-mAb Display on Progenitor B Cells.
    Hellmann I; Waldmeier L; Bannwarth-Escher MC; Maslova K; Wolter FI; Grawunder U; Beerli RR
    Front Immunol; 2018; 9():2490. PubMed ID: 30450096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An EGFR-targeting antibody-drug conjugate LR004-VC-MMAE: potential in esophageal squamous cell carcinoma and other malignancies.
    Hu XY; Wang R; Jin J; Liu XJ; Cui AL; Sun LQ; Li YP; Li Y; Wang YC; Zhen YS; Miao QF; Li ZR
    Mol Oncol; 2019 Feb; 13(2):246-263. PubMed ID: 30372581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zolbetuximab for Claudin18.2-positive gastric or gastroesophageal junction cancer.
    Kubota Y; Shitara K
    Ther Adv Med Oncol; 2024; 16():17588359231217967. PubMed ID: 38188462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CMG901, a Claudin18.2-specific antibody-drug conjugate, for the treatment of solid tumors.
    Xu G; Liu W; Wang Y; Wei X; Liu F; He Y; Zhang L; Song Q; Li Z; Wang C; Xu R; Chen B
    Cell Rep Med; 2024 Sep; 5(9):101710. PubMed ID: 39232496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancing antitumor efficacy of CLDN18.2-directed antibody-drug conjugates through autophagy inhibition in gastric cancer.
    Xue W; Xu C; Zhang K; Cui L; Huang X; Nan Y; Ju D; Chang X; Zhang X
    Cell Death Discov; 2024 Sep; 10(1):393. PubMed ID: 39227365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.